Akili, Inc.

AKLI

US00974B1070

Advanced Medical Equipment & Technology

End-of-day quote Nasdaq Other stock markets 23:00:00 09/05/2024 BST			5-day change	1st Jan Change
0.4272 ^USD	-3.87%		+6.37%	-12.30%

04-30	Akili, Inc. Plans to Continue to Pursue Marketing Authorization from the U.S. Food and Drug Administration for Its EndeavorOTC Product	CI
04-30	Akili, Inc. to Reduce Workforce	CI

Akili, Inc. Announces Resignation of Santosh Shanbhag as Chief Financial Officer, Effective on January 12, 2024

January 05, 2024 at 09:18 pm

On January 3, 2024, Santosh Shanbhag submitted his resignation as Chief Financial Officer of Akili, Inc. effective as of January 12, 2024, to pursue another business opportunity.

Latest news about Akili, Inc.

Akili, Inc. Plans to Continue to Pursue Marketing Authorization from the U.S. Food and Drug Administration for Its EndeavorOTC Product	04-30	CI
Akili, Inc. to Reduce Workforce	04-30	CI
Akili, Inc. Announces an Amendment to its Strategic Distribution Agreement with Shionogi & Co., Ltd	04-30	CI
Akili, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	02-29	CI
Akili, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	02-29	CI
Earnings Flash (AKLI) AKILI Posts Q4 Revenue $749,000, vs. Street Est of $0.78M	02-29	MT
Sector Update: Health Care Stocks Ease Late Afternoon	02-26	MT
Akili Shares More Than Double After Submission of ADHD Treatment for Marketing Approval in Japan	02-26	MT
Akili's Japan Partner Submits SDT-001 for Marketing Approval in Japan	02-26	DJ
Akili Announces Positive Results from Shionogi's Phase 3 Clinical Trial of Localized Version of Akili's Endeavorrx®? for Pediatric Adhd Patients in Japan	02-26	CI
Akili Appoints John Spinale to the Board and Audit Committee	02-21	CI
Akili, Inc. Announces Executive Changes, Effective on January 12, 2024	01-05	CI
Akili, Inc. Announces Resignation of Santosh Shanbhag as Chief Financial Officer, Effective on January 12, 2024	01-05	CI
Akili, Inc. Announces Kenneth Ehlert Resigns as A Member of the Board of Director, Member of the Audit Committee and Nominating and Corporate Governance Committee of the Board	12-20	CI
Akili, Inc. Receives Authorization from the U.S. Food and Drug Administration	12-18	CI
Transcript : Akili, Inc., Q3 2023 Earnings Call, Nov 09, 2023	11-09
Earnings Flash (AKLI) AKILI Reports Q3 Revenue $702,000	11-09	MT
Akili, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-09	CI
Top Premarket Decliners	26/10/23	MT
Akili, Inc. Releases Results from A New Study Examining the Way in Which Adhd Impacting the U.S. Workforce	12/10/23	CI
Akili Names Matt Franklin as Chief Executive, Eddie Martucci as Board Chair	06/10/23	MT
Akili, Inc. Announces Executive Changes	06/10/23	CI
Akili, Inc. Announces CEO Changes	06/10/23	CI
Akili Releases EndeavorOTC on Android Devices, Expanding Treatment Access for Millions of Adults with Adhd	21/09/23	CI
Transcript : Akili, Inc. - Special Call	14/09/23

Akili, Inc. is a digital medicine company engaged in the development of cognitive treatments through technologies. The Companyâs approach of developing and commercializing technologies is designed to directly target the physiology of the brain. Its therapeutic engines are designed to target cognitive functions with the potential to address multiple medical conditions presenting the same functional cognitive impairments. Its product, EndeavorRx, is indicated for use to improve attention function for children ages 8-17 with primarily inattentive or combined-type attention-deficit/hyperactivity disorder (ADHD), who have a demonstrated attention issue. Its product, EndeavorOTC, which is built on the same platform as EndeavorRx, nationwide without a prescription to improve attention function, ADHD symptoms and quality of life in adults 18 years of age and older with primarily inattentive or combined type ADHD. In addition, the Company has several investigator-initiated studies.

Sector

Advanced Medical Equipment & Technology

Calendar

13/05/2024 - Q1 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Ratings for Akili, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

0.4272 USD

Average target price

0.65 USD

Spread / Average Target

+52.15%

Consensus

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Advanced Medical Equipment & Technology

	1st Jan change	Capi.
AKILI, INC.	-12.30%	33.58M
THERMO FISHER SCIENTIFIC	+11.73%	226B
DANAHER CORPORATION	+9.53%	188B
INTUITIVE SURGICAL, INC.	+14.63%	137B
BOSTON SCIENTIFIC CORPORATION	+27.47%	108B
SIEMENS HEALTHINEERS AG	-0.04%	63.19B
EDWARDS LIFESCIENCES CORPORATION	+13.73%	52.26B
SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.	+4.86%	51B
AGILENT TECHNOLOGIES, INC.	+7.72%	43.89B
GE HEALTHCARE TECHNOLOGIES INC.	+7.86%	38.07B

Other Advanced Medical Equipment & Technology

Akili, Inc.

Equities

AKLI

US00974B1070

Advanced Medical Equipment & Technology

Akili, Inc. Announces Resignation of Santosh Shanbhag as Chief Financial Officer, Effective on January 12, 2024

Latest news about Akili, Inc.

Chart Akili, Inc.

Company Profile

Income Statement Evolution

Ratings for Akili, Inc.

Analysts' Consensus

Quarterly earnings - Rate of surprise

Sector Other Advanced Medical Equipment & Technology